1. Search Result
Search Result
Results for "

JAK2/STAT3 Iinhibitor

" in MedChemExpress (MCE) Product Catalog:

399

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

4

Biochemical Assay Reagents

18

Peptides

2

Inhibitory Antibodies

72

Natural
Products

6

Recombinant Proteins

22

Isotope-Labeled Compounds

9

Antibodies

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P10114

    PpYLKTK-mts; STAT3 PI

    STAT Cancer
    STAT3-IN-24, cell-permeable (PpYLKTK-mts) is a STAT3 peptide inhibitor. STAT3-IN-24, cell-permeable inhibits recruitment of STAT3 to Jak2 and phosphorylation of Y705, thus preventing the dimerization and the nuclear translocation of STAT3 .
    <em>STAT3</em>-IN-24, cell-permeable
  • HY-131194

    Interleukin Related Cancer
    JAK2/STAT3-IN-1 (compound (S)-10a) is a potent GP130 inhibitor with an IC50 of 3.04 µM. JAK2/STAT3-IN-1 shows anti-tumor activity .
    <em>JAK2</em>/<em>STAT3</em>-IN-1
  • HY-146066

    nAChR JAK STAT NO Synthase Inflammation/Immunology
    α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC50 value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .
    α7 nAchR-<em>JAK2</em>-<em>STAT3</em> agonist 1
  • HY-112391

    JAK STAT Cancer
    SD-1029 is a JAK2/STAT3 inhibitor . SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation [2].
    SD-1029
  • HY-P10115

    STAT Cancer
    APT STAT3 is a specific STAT3-binding peptide. APT STAT3 can bind STAT3 with high specificity and affinity (~231 nmol/L). APT STAT3 is a tractable agent for translation to target the broad array of cancers harboring constitutively activated STAT3 .
    APT <em>STAT3</em>
  • HY-153023

    PROTACs STAT Cancer
    PROTAC STAT3 degrader-2 is a selective and efficacious PROTAC degrader of STAT3 protein with a DC50 of 3.54 μM in Molm-16 Cell. PROTAC STAT3 degrader-2 has the potential for cancer research . PROTAC STAT3 degrader-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    PROTAC <em>STAT3</em> degrader-<em>2</em>
  • HY-155746

    JAK Infection Inflammation/Immunology
    JAK2-IN-9 (Compound A8) is a selective JAK2 inhibitor (IC50: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs) .
    <em>JAK2</em>-IN-9
  • HY-N1356

    JAK STAT NF-κB Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    Reticuline shows anti-inflammatory effects through JAK2/STAT3 and NF-κB signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3 . Reticuline exhibits cardiovascular effects [2].
    Reticuline
  • HY-150251

    STAT PROTACs Cancer
    STAT3 degrader-2 is a PROTAC-based degrader of STAT3. STAT3 degrader-2 can degrade the level of total STAT3 protein. STAT3 degrader-2 can be used for the research of cancer and other diseases . STAT3 degrader-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    <em>STAT3</em> degrader-<em>2</em>
  • HY-147048

    STAT Cancer
    STAT3 degrader-1 (compound 295) is a potent STAT3 degrader. STAT3 degrader-1 can be used for researching anticancer . STAT3 degrader-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    <em>STAT3</em> degrader-1
  • HY-149007
    STAT3-IN-11
    1 Publications Verification

    STAT Apoptosis Cancer
    STAT3-IN-11 (7a) is a selective STAT3 inhibitor that inhibits the phosphorylation of STAT3 at site pTyr705. STAT3-IN-11 inhibits the phosphorylation of downstream genes (Survivin and Mcl-1) without affecting its upstream tyrosine kinases (Src and JAK2) levels and p-STAT1 expression. STAT3-IN-11 can induce cancer cell apoptosis, which is potential for the discovery of effective STAT3 inhibitors and antitumor agents against cancers .
    <em>STAT3</em>-IN-11
  • HY-102055
    JAK2 JH2 Tracer
    4 Publications Verification

    JAK Others
    JAK2 JH2 Tracer (Tracer 5) is a fluorescent probe for JAK2 JH2 domain, with a Kd of value 0.2 μM [2].
    <em>JAK2</em> JH<em>2</em> Tracer
  • HY-146186

    JAK Cancer
    JAK2 JH2 binder-1 (compound 11) is a potent and selective JAK2 JH2 binder, with a Kd of 37.1 nM. JAK2 JH2 binder-1 has the potential for various myeloproliferative neoplasms research .
    <em>JAK2</em> JH<em>2</em> binder-1
  • HY-149647

    Others Inflammation/Immunology
    HA-2a can inhibit the JAK2/STAT3 pathway via downregulates circDcbld2 expression in RAW264.7 cells .
    HD-<em>2</em>a
  • HY-15480
    NSC 42834
    1 Publications Verification

    JAK2 Inhibitor V; Z3

    JAK Cancer
    NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of Jak2, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.
    NSC 42834
  • HY-RS07018

    Small Interfering RNA (siRNA) Others

    JAK2 Human Pre-designed siRNA Set A contains three designed siRNAs for JAK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    JAK2 Human Pre-designed siRNA Set A
    JAK2 Human Pre-designed siRNA Set A
  • HY-RS07019

    Small Interfering RNA (siRNA) Others

    Jak2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Jak2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Jak2 Mouse Pre-designed siRNA Set A
    Jak2 Mouse Pre-designed siRNA Set A
  • HY-RS07020

    Small Interfering RNA (siRNA) Others

    Jak2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Jak2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Jak2 Rat Pre-designed siRNA Set A
    Jak2 Rat Pre-designed siRNA Set A
  • HY-155808

    STAT JAK Apoptosis COX Cancer
    STAT3-IN-18 (compound SPP) is a platinum (IV) complex with an axial ligand derived from sandalwood. STAT3-IN-18 inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, with anti-proliferative activity. STAT3-IN-18 activates caspase-3 and increases cleaved polyADP-ribose polymerase to induce apoptosis. STAT3-IN-18 promotes maturation and antigen presentation of dendritic cells and demonstrates safety in vivo.
    <em>STAT3</em>-IN-18
  • HY-RS13888

    Small Interfering RNA (siRNA) Others

    STAT3 Human Pre-designed siRNA Set A contains three designed siRNAs for STAT3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    STAT3 Human Pre-designed siRNA Set A
    STAT3 Human Pre-designed siRNA Set A
  • HY-RS13889

    Small Interfering RNA (siRNA) Others

    Stat3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Stat3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Stat3 Mouse Pre-designed siRNA Set A
    Stat3 Mouse Pre-designed siRNA Set A
  • HY-RS13890

    Small Interfering RNA (siRNA) Others

    Stat3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Stat3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Stat3 Rat Pre-designed siRNA Set A
    Stat3 Rat Pre-designed siRNA Set A
  • HY-124858

    STAT JAK Apoptosis Cardiovascular Disease Cancer
    SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities [2] [3].
    SC99
  • HY-113573

    PTA

    JAK STAT Inflammation/Immunology
    Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses JAK2/STAT3-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3 .
    Protosappanin A
  • HY-N1405
    Cucurbitacin I
    5+ Cited Publications

    Elatericin B; JSI-124; NSC-521777

    STAT JAK Cancer
    Cucurbitacin I is a natural selective inhibitor of JAK2/STAT3, with potent anti-cancer activity.
    Cucurbitacin I
  • HY-P1590

    JAK Inflammation/Immunology Cancer
    Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.
    Tyrosine Protein Kinase <em>JAK 2</em> (Phospho-Tyr8, 9)
  • HY-115452

    JAK Apoptosis Cancer
    G5-7, an orally active and allosteric JAK2 inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr 1068) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect. G5-7 has the potential for glioma study .
    G5-7
  • HY-12000
    AG490
    95+ Cited Publications

    Tyrphostin AG490; Tyrphostin B42

    EGFR STAT JAK Autophagy Cancer
    AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.
    AG490
  • HY-N1535
    Ponicidin
    2 Publications Verification

    Rubescensine B

    Apoptosis Inflammation/Immunology Cancer
    Ponicidin (Rubescensine B) is a diterpenoid derived from Rabdosia rubescens, and exhibits immunoregulatory, anti-inflammatory, anti-viral and anti-cancer activity. Ponicidin (Rubescensine B) induces apoptosis of gastric carcinoma cell, decreases the phosphorylation of JAK2 and STAT3, and shows no effect on protein levels of JAK2 and STAT3 .
    Ponicidin
  • HY-100544
    FLLL32
    5 Publications Verification

    FLLL32, a synthetic analog of curcumina, is a JAK2/STAT3 dual inhibitor with anti-tumor activity. FLLL32 can inhibit the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells [2].
    FLLL32
  • HY-N0635
    Prim-O-glucosylcimifugin
    2 Publications Verification

    NO Synthase COX Inflammation/Immunology
    Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by through regulating JAK2/STAT3 signaling.
    Prim-O-glucosylcimifugin
  • HY-150603

    STAT Apoptosis Bcl-2 Family Cancer
    STAT3-IN-13 (compound 6f) is a potent STAT3 inhibitor. STAT3-IN-13 has anti-proliferative effects and binds to the STAT3 SH2 domain with a KD of 0.46 μM. STAT3-IN-13 inhibits the phosphorylation of STAT3 Y705 and downstream target gene expression. STAT3-IN-13 induces apoptosis in vitro and suppresses the growth and metastasis of tumor in vivo. STAT3-IN-13 can be used for cancer research .
    <em>STAT3</em>-IN-13
  • HY-N1405R

    Elatericin B (Standard); JSI-124 (Standard); NSC-521777 (Standard)

    STAT JAK Cancer
    Cucurbitacin I (Standard) is the analytical standard of Cucurbitacin I. This product is intended for research and analytical applications. Cucurbitacin I is a natural selective inhibitor of JAK2/STAT3, with potent anti-cancer activity [2].
    Cucurbitacin I (Standard)
  • HY-137756

    JAK Cancer
    JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective JAK2 inhibitor with an IC50 of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells .
    <em>JAK2</em>-IN-6
  • HY-N10472

    STAT Cancer
    STAT3-IN-14 (Compound 1) is a STAT3 inhibitor and has STAT3 phosphorylation inhibitory activity. STAT3-IN-14 (Compound 1) can directly bind to the hinge region of STAT3 .
    <em>STAT3</em>-IN-14
  • HY-128588
    STAT3-IN-3
    4 Publications Verification

    STAT Apoptosis Cancer
    STAT3-IN-3 is a potent and selective inhibitor of signal transducer and activator of transcription 3 (STAT3), with anti-proliferative activity. STAT3-IN-3 induces apoptosis in breast cancer cells. STAT3-IN-3 acts as a promising mitochondria-targeting STAT3 inhibitor for cancer research .
    <em>STAT3</em>-IN-<em>3</em>
  • HY-15312
    WP1066
    20+ Cited Publications

    STAT JAK Apoptosis Cancer
    WP1066 is an inhibitor of JAK2 and STAT3, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3.
    WP1066
  • HY-107595

    JAK STAT Apoptosis Cancer
    SD-1008 is a potent JAK inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances apoptosis induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway .
    SD-1008
  • HY-155982

    STAT Cancer
    STAT3-IN-20 (Compound 40) is a selective STAT3 inhibitor (IC50: 0.65 μM). STAT3-IN-20 binds the SH2 domain to inhibit STAT3 phosphorylation, translocation, and downstream gene transcription. STAT3-IN-20 exhibits antiproliferative activities against STAT3-overactivated DU145 and MDA-MB-231 cancer cells (IC50: 2.97 μM and 3.26 μM respectively). STAT3-IN-20 induces cell cycle arrest and apoptosis .
    <em>STAT3</em>-IN-20
  • HY-123524

    STAT Cancer
    STAT3-IN-4 (compound B9) is a STAT3 inhibitor with Kd values for STAT3 (I634S/Q635G) and WT are 22.75 and 4.59 μM, respectively. STAT3-IN-4 can inhibit the proliferation of tumor cells .
    <em>STAT3</em>-IN-4
  • HY-161136

    EGFR STAT Cancer
    EGFR/STAT3-IN-1 (Compound 5k) is a dual inhibitor of EGFR/STAT3 with IC50 values for EGFR and STAT3 are 41 and 3.34 nM, respectively. EGFR/STAT3-IN-1 has antitumor activity .
    EGFR/<em>STAT3</em>-IN-1
  • HY-144870

    STAT Cancer
    STAT3-IN-7, an aryl sulfonamido azetidine compound, is an orally active STAT3 inhibitor. STAT3-IN-7 has anticancer activities (WO2021016333A1, H182) .
    <em>STAT3</em>-IN-7
  • HY-121471
    Chrysoeriol
    1 Publications Verification

    Endogenous Metabolite Metabolic Disease
    Chrysoeriol is a kind of natural yellow ash, which can be used for heating plants Coronopus didymus. Chrysoeriol suppresses the JAK2/STAT3, IκB/p65, and NF-κB pathways, and has strong anti-inflammatory activity.
    Chrysoeriol
  • HY-148748

    JAK STAT p38 MAPK Others
    Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of human platelets in mouse xenotransplantation assay .
    Butyzamide
  • HY-143884

    JAK Inflammation/Immunology
    JAK2/TYK2-IN-2 is a potent and selective TYK2 inhibitor with IC50 values of 9 and 157 nM for TYK2 and JAK2, respectively. JAK2/TYK2-IN-2 has anti-inflammatory activity .
    <em>JAK2</em>/TYK<em>2</em>-IN-1
  • HY-N2963

    ERK p38 MAPK JAK STAT TNF Receptor Interleukin Related COX Arginase Inflammation/Immunology
    Broussonin E is a phenolic compound and shows anti-inflammatory activity. Broussonin E can suppress inflammation by modulating macrophages activation statevia inhibiting the ERK and p38 MAPK and enhancing JAK2-STAT3 signaling pathway. Broussonin E can be used for the research of inflammation-related diseases such as atherosclerosis .
    Broussonin E
  • HY-13775
    XL019
    4 Publications Verification

    JAK Apoptosis Cancer
    XL019 is a potent, orally active, and selective JAK2 inhibitor, with IC50s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2 [2].
    XL019
  • HY-151577

    STAT Apoptosis Cancer
    STAT3-SH2 domain inhibitor 1 is a potent Src Homology 2 (SH2) Domain of STAT3 (STAT3-SH2 domain) inhibitor with a Kd value of 1.57 μM. STAT3-SH2 domain inhibitor 1 inhibits STAT3 signaling transduction and transcriptional activation. STAT3-SH2 domain inhibitor 1 induces apoptosis in gastric cancer cells. STAT3-SH2 domain inhibitor 1 can be used in research of cancer .
    <em>STAT3</em>-SH<em>2</em> domain <em>inhibitor</em> 1
  • HY-155807

    STAT JAK Apoptosis Cancer
    DPP is a Platinum(IV) complex, bearing pterostilbene-derived axial ligand. DPP inhibit the JAK2-STAT3 pathway in breast cancer (BC) cells with antiproliferative activity, and activates caspase-3 and cleaved poly ADP-ribose polymerase to induces apoptosis. DPP promotes the maturation and antigen presentation of dendritic cells, and exhibits in vivo safety .
    DPP
  • HY-107459

    (E/Z)-Tyrphostin AG490; (E/Z)-Tyrphostin B42

    EGFR STAT JAK Cancer
    (E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.
    (E/Z)-AG490

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: